FILE:BIIB/BIIB-8K-20090330160036.txt.gz
EVENTS:	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
TEXT:
ITEM: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (General Instruction A.2. below):
see
 
 
 
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
     Robert A. Hamm was named Chief Operating Officer of Biogen Idec Inc. effective March 30, 2009. Mr. Hamm replaces Hans Peter Hasler, who resigned from the position of Chief Operating Officer effective March 30, 2009.
     Mr. Hamm, age 57, has served in various capacities at Biogen Idec Inc. and at Biogen, Inc. before the merger with IDEC Pharmaceuticals Corporation in November 2003, including: Executive Vice President, Pharmaceutical Operations & Technology (October 2007  March 2009); Senior Vice President, Neurology Strategic Business Unit (January 2006  October 2007); Senior Vice President, Immunology Business Unit (November 2002  January 2006); Senior Vice President  Europe, Africa, Canada and Middle East (October 2001  November 2002); Vice President  Sales and Marketing (October 2000  October 2001); Vice President  Manufacturing (June 1999  October 2000); Director, Northern Europe and Distributors (November 1996  June 1999); and Associate Director, Logistics (April 1994  November 1996).
     As Chief Operating Officer, Mr. Hamm's base salary will be $720,000 per year and his target annual cash incentive opportunity will be 75% of base salary. In connection with his appointment, Mr. Hamm will receive awards of time-vested restricted stock units with a value of approximately $190,000, performance-vested restricted stock units with a value of approximately $190,000, and options to purchase shares of Biogen Idec common stock with a value of approximately $190,000. Each of these awards will be granted under the Biogen Idec Inc. 2008 Omnibus Equity Plan. The number of shares subject to each award will be based on the closing price of Biogen Idec common stock on April 1, 2009, the first trading day of the month following Mr. Hamm's appointment.
 
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 30, 2009


